Short Interest in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Drops By 36.1%

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 31,224 shares, a drop of 36.1% from the November 30th total of 48,866 shares. Based on an average trading volume of 33,544 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.1% of the shares of the stock are short sold. Currently, 0.1% of the shares of the stock are short sold. Based on an average trading volume of 33,544 shares, the days-to-cover ratio is presently 0.9 days.

Nanobiotix Price Performance

NASDAQ:NBTX traded down $0.82 during trading hours on Tuesday, reaching $21.67. 28,831 shares of the company traded hands, compared to its average volume of 35,752. Nanobiotix has a 1-year low of $2.82 and a 1-year high of $30.35. The firm’s 50-day moving average is $21.00 and its 200-day moving average is $14.14.

Wall Street Analysts Forecast Growth

NBTX has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Wednesday, October 8th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $11.00.

Institutional Trading of Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. bought a new position in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.